DNA Ploidy and S-phase Fraction Analyses of Hyperplastic, Atypical and Cancerous Endometrium Using Flow Cytometry from Paraffin-embedded Tissues

Pervez, Shahid; Hitchcock, Andrew; Sinton, T. M.; Mani, Anju; Smith, J. L.

doi:10.1078/0344-0338-00178

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MtDNA, in fact, replicates independently from nDNA so that copies of mtDNA per cell can change under different cell conditions [6]. Since changes in the ploidy have rarely been reported in hyperplasia and type I endometrial cancer [20], the mtDNA/nDNA ratio could indicate increases or decreases in mtDNA copy number per single cell.…”

Section: Discussionmentioning

confidence: 99%

Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium

et al. 2012

View full text Add to dashboard Cite

BackgroundAn increase in mitochondrial DNA (mtDNA) content and mitochondrial biogenesis associated with the activation of PGC-1α signalling pathway was previously reported in type I endometrial cancer. The aim of this study has been to evaluate if mtDNA content and the citrate synthase (CS) activity, an enzyme marker of mitochondrial mass, increase in progression from control endometrium to hyperplasia to type I endometrial carcinoma.ResultsGiven that no statistically significant change in mtDNA content and CS activity in endometrium taken from different phases of the menstrual cycle or in menopause was found, these samples were used as control. Our research shows, for the first time, that mtDNA content and citrate synthase activity increase in hyperplastic endometrium compared to control tissues, even if their levels remain lower compared to cancer tissue. In particular, mtDNA content increases seem to precede increases in CS activity. No statistically significant change in mtDNA content and in CS activity was found in relation to different histopathological conditions such as grade, myometrial invasion and stage.ConclusionMtDNA content and citrate synthase activity increases in pre-malignant lesions could be a potential molecular marker for progression from hyperplasia to carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, the experience of other authors seem to confirm that aneuploidy rarely occurs among endometrial hyperplasias, whereas elevated S-phase fraction may indicate an increased risk to develop endometrial carcinoma. 39,40 In our experience, other tools such as the immunostaining evaluation of the expression of the retinoblastoma-related gene Rb2/ p130 may be diagnostically useful in the often difficult distinction between hyperplastic and atypical hyperplastic endometrium. 41 The current management of endometrial cancer patients includes THBSO.…”

Section: Discussionmentioning

confidence: 99%

Ten‐year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma

Susini

Amunni

Molino

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.To improve the outcome of endometrial cancer patients, a more accurate prognostic assessment is mandatory. The aims of the study were to evaluate the role of flow cytometric DNA ploidy as an independent prognostic factor in patients with endometrial cancer and to verify if ploidy was able to distinguish patients with different prognosis into homogeneous subgroups for grade of differentiation and stage.METHODS.In a prospective study, DNA ploidy was evaluated from fresh tumor samples in 174 endometrial cancer patients who underwent surgery as the first treatment. Ploidy, as well as classical parameters, were analyzed in relation to the length of disease‐free survival and disease‐specific survival.RESULTS.DNA aneuploidy was found in 49 patients (28.2%). Patients with DNA‐aneuploid tumors had a significantly reduced disease‐free interval and disease‐specific survival (P < .0001). The 10‐year survival probability was 53.2% for DNA‐aneuploid patients and 91.0% for patients with DNA‐diploid tumors. By multivariate analysis DNA‐aneuploid type was the strongest independent predictor of poor outcome, followed by age and stage. Patients with DNA‐aneuploid tumor had a significantly higher risk ratio for recurrence (5.03) and death due to disease (6.50) than patients with DNA‐diploid tumors. Stratification by DNA‐ploidy within each group by grade of differentiation allowed identification of patients with significantly different outcome. In grade 2 tumors, 10‐year survival was 45.0% in aneuploid cases and 91.9% in diploid cases (P < .0001). Patients with advanced‐stage (>I) diploid tumor did significantly better than patients with stage I aneuploid tumor (P = .04).CONCLUSIONS.The presence of DNA‐aneuploid type in endometrial cancer identifies high‐risk cases among the patients considered ‘low risk’ according to stage and grade of differentiation. Cancer 2007. © 2007 American Cancer Society.

show abstract

Significance of immunohistochemistry and DNA ploidy in differential diagnosis of flat urothelial lesions and conditions using CK20, p53, CD44, ErbB-2, and image cytometry

Elsayed¹,

Abdul-Maksoud²

2016

Egyptian Journal of Pathology

View full text Add to dashboard Cite

DNA Ploidy and S-phase Fraction Analyses of Hyperplastic, Atypical and Cancerous Endometrium Using Flow Cytometry from Paraffin-embedded Tissues

Cited by 3 publications

References 13 publications

Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium

Mitochondrial DNA content and mass increase in progression from normal to hyperplastic to cancer endometrium

Ten‐year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma

Significance of immunohistochemistry and DNA ploidy in differential diagnosis of flat urothelial lesions and conditions using CK20, p53, CD44, ErbB-2, and image cytometry

Contact Info

Product

Resources

About